Across 150 European CTIS endocrinology Phase III trials, 86 trials included a CTIS-listed CRO or outsourced trial-support provider, equal to 57.3% of the cohort. IQVIA was the most active named provider with 43/86 CRO-supported trials, followed by ICON Clinical Research with 28/86 and 4G Clinical with 17/86. CRO need rises sharply with operational scale: 30/31 trials spanning 7+ countries and 32/35 trials with 26+ sites used CRO support.
CRO support appeared in 86/150 trials overall. The CRO-supported share was 33/63 in 2024 trials, 24/46 in 2025 trials, and 29/41 in 2026 trials, rising from roughly half of trials to 70.7% in the 2026 cohort.
The 2026 cohort shows heavier reliance on outsourced execution. In CTIS terms, this points to rising dependence on vendors that can coordinate EU submissions, country-level Part II packages, site activation, laboratories, data systems, and patient-facing tools in parallel.
Among 86 CRO-supported trials, IQVIA appeared in 43 trials, ICON Clinical Research in 28 trials, and 4G Clinical in 17 trials. IQVIA alone was present in 50.0% of CRO-supported trials and 28.7% of the full 150-trial cohort.
| Provider | Trials | Share of CRO trials | Dominant role pattern |
|---|---|---|---|
| IQVIA | 43 | 50.0% | Clinical operations and central/special lab support |
| ICON Clinical Research | 28 | 32.6% | Central lab and broad CRO support |
| 4G Clinical | 17 | 19.8% | RTSM/IWRS and randomisation support |
| Medidata | 13 | 15.1% | Data platforms and clinical systems |
| Bioclinica | 13 | 15.1% | Imaging, ECG, central reading |
| Labcorp | 12 | 14.0% | Central laboratory support |
| PPD / Thermo Fisher | 10 | 11.6% | Lab, safety, statistics, clinical ops |
| Suvoda | 10 | 11.6% | DTP, reimbursement, RTSM support |
| Altasciences | 9 | 10.5% | Lab and clinical operations |
| Syneos Health | 8 | 9.3% | Lab and clinical operations |
The CRO market is not only full-service clinical operations. The leading CTIS-listed providers cover distinct outsourcing layers: IQVIA and ICON dominate broad clinical and lab-linked support, while 4G Clinical, Medidata, Bioclinica, Labcorp, and Suvoda reflect specialist outsourcing around RTSM, data systems, imaging, labs, and patient logistics.
Only 11/67 single-country trials used CRO support, equal to 16.4%. Once trials reached 2–3 countries, CRO support rose to 16/19 trials, equal to 84.2%, and at 7+ countries it reached 30/31 trials, equal to 96.8%.
The strongest outsourcing trigger is not simply Phase III status; it is CTIS multi-country execution. Once Part II country coordination expands beyond one country, CRO use becomes the dominant operating model.
CRO support was present in 9/47 trials with 1–3 sites, but rose to 29/37 trials with 11–25 sites and 32/35 trials with 26+ sites. By planned sample size, CRO support increased from 23/56 trials below 100 participants to 31/38 trials with 500+ participants.
The practical CRO threshold is around 11+ sites or 500+ planned participants. At that point, trial execution shifts from sponsor-led local delivery to outsourced site coordination, central services, recruitment support, and CTIS country operations.
Obesity/overweight was the dominant CRO demand area, with 36/51 trials using CRO support. Type 2 diabetes followed with 15/22 CRO-supported trials. Smaller but high-outsourcing indications included dyslipidaemia at 7/8, phenylketonuria at 4/5, and NASH/metabolic liver disease at 4/4.
| Indication cluster | CRO-supported | All trials | CRO share |
|---|---|---|---|
| Obesity / overweight | 36 | 51 | 70.6% |
| Type 2 diabetes | 15 | 22 | 68.2% |
| Dyslipidaemia | 7 | 8 | 87.5% |
| Diabetes / glycaemic control | 5 | 17 | 29.4% |
| Adrenal / cortisol disorders | 4 | 6 | 66.7% |
| Phenylketonuria (PKU) | 4 | 5 | 80.0% |
| NASH / metabolic liver disease | 4 | 4 | 100.0% |
| CKD-mineral / parathyroid disorders | 2 | 5 | 40.0% |
The main commercial demand pool is obesity and adjacent metabolic disease. Rare metabolic indications show high CRO share, but obesity and type 2 diabetes create the largest absolute market because they combine high trial volume with multi-country, multi-site Phase III execution.
Among 86 CRO-supported trials, 75 outsourced central or special laboratory, PK, or biomarker testing; 63 outsourced data platforms, CRF, safety database, or eTMF functions; and 51 outsourced imaging, ECG, or central reading. Broad CRO clinical operations or site support appeared in 49/86 CRO-supported trials.
The highest-value outsourcing need is not only monitoring. Endocrinology Phase III trials frequently need central lab, metabolic biomarkers, PK/antibody testing, eCRF/safety databases, RTSM/IWRS, eCOA/ePRO, imaging, ECG, and patient logistics vendors that can be coordinated across EU submissions and local country activations.
CRO support was present in 40/45 trials with digital or remote recruitment, 13/14 trials using registry or advocacy recruitment, 28/35 paediatric trials, and 23/26 orphan-drug trials. Adaptive or dose-adjusted designs and biomarker-stratified designs were smaller groups, but both showed 100.0% CRO support.
| Feature | CRO-supported | Feature trials | CRO share |
|---|---|---|---|
| Digital / remote recruitment | 40 | 45 | 88.9% |
| Registry / advocacy recruitment | 13 | 14 | 92.9% |
| Orphan-drug trials | 23 | 26 | 88.5% |
| Paediatric trials | 28 | 35 | 80.0% |
| Adaptive / dose-adjusted design | 8 | 8 | 100.0% |
| Biomarker-stratified design | 3 | 3 | 100.0% |
| Randomised design | 59 | 87 | 67.8% |
CRO need is highest when the sponsor must manage specialised consent pathways, orphan or paediatric recruitment, digital recruitment assets, registry engagement, biomarker stratification, and adaptive dosing. These features add operational and CTIS documentation burden even when sample size is modest.
CRO-supported trials accounted for 477/567 CTIS country appearances, equal to 84.1%, and 2,374/2,726 sites, equal to 87.1%. Germany, Poland, and Spain were the largest CRO-supported site markets, with 360, 333, and 304 CRO-supported sites respectively.
| Country | CRO site count | All sites | CRO trial-country share |
|---|---|---|---|
| Germany | 360 | 393 | 61/75 · 81.3% |
| Poland | 333 | 344 | 54/59 · 91.5% |
| Spain | 304 | 341 | 52/59 · 88.1% |
| Italy | 217 | 250 | 37/47 · 78.7% |
| France | 186 | 249 | 35/47 · 74.5% |
| Bulgaria | 151 | 151 | 21/21 · 100.0% |
| Czechia | 142 | 146 | 27/28 · 96.4% |
| Belgium | 111 | 129 | 28/33 · 84.8% |
| Hungary | 108 | 109 | 19/20 · 95.0% |
| Romania | 71 | 81 | 15/16 · 93.8% |
For CRO targeting, Germany, Poland, Spain, Italy, and France are the highest-volume country footprints. Under CTIS, these countries matter because Part II documentation, site readiness, contracts, patient materials, and local recruitment execution must be coordinated country by country.
Biomarker or metabolic laboratory endpoints appeared in 87/150 trials, safety/adverse-event endpoints in 70/150, patient-reported outcomes in 53/150, weight/BMI endpoints in 48/150, PK endpoints in 28/150, and imaging/body-composition endpoints in 18/150.
| Endpoint category | Trials with category | CRO-supported | CRO share |
|---|---|---|---|
| Biomarker / metabolic laboratory | 87 | 57 | 65.5% |
| Safety / adverse events | 70 | 49 | 70.0% |
| Patient-reported outcomes | 53 | 31 | 58.5% |
| Weight / BMI | 48 | 41 | 85.4% |
| PK endpoints | 28 | 23 | 82.1% |
| Imaging / body composition | 18 | 11 | 61.1% |
The endpoint profile matches the outsourcing pattern: metabolic biomarkers, PK, safety databases, ePRO/eCOA, imaging, DXA/MRI/MRE, and central ECG or lab reads create a specialized vendor layer beyond standard site monitoring.
All 86 CRO-supported trials were pharma or biotech-sponsored. CRO support appeared in 86/110 pharma or biotech-sponsored trials, equal to 78.2%, while 0/40 non-pharma sponsor trials listed CRO support in the CTIS sponsor variable.
The commercial CRO opportunity in this dataset is concentrated in pharma and biotech-sponsored trials. Academic, hospital, and other non-pharma sponsors are visible in CTIS, but their reported third-party pattern is much less CRO-driven.
CTIS means the Clinical Trials Information System used for EU clinical trial submissions. Part II refers to country-specific assessment and documentation, including site, investigator, informed consent, recruitment, and local feasibility elements. CRO-supported means a trial where the CTIS sponsor variable listed at least one CRO or trial-support provider under CRO-present records.